37 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Advani, Medical Oncologist in Stanford, CA?
Dr. Ranjana Advani, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She has been practicing for over 37 years and is board certified by the American Board of Internal Medicine. Dr. Advani graduated from Bombay University, K.J. Somaiya Medical College And Research Centre and completed her residency at Stanford University School of Medicine. Dr. Advani is fluent in English and German, and is currently seeing new patients. Dr. Advani’s practice accepts Cigna, Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Advani’s office at (650) 498-6000.
What are Areas of Expertise for Dr. Advani?
Dr. Ranjana Advani, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Advani empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin's, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Advani is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Advani go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University School of Medicine | Stanford University Program
Medical School: Bombay University, K.J. Somaiya Medical College And Research Centre | Butler University in Indianapolis | Grant Government Medical College
Is Dr. Advani board certified in Medical Oncologist?
Yes, Dr. Ranjana Advani, MD is board certified by the American Board of Internal Medicine since 1995
What languages does Dr. Advani speak?
Dr. Advani and their clinical team can communicate with patients in the following languages:
English
German
What conditions does Dr. Advani treat?
As a Medical Oncologist, Dr. Advani diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Advani. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Diffuse Large B-cell Lymphoma
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Waldenstrom Macroglobulinemia
- B-cell Lymphoma
- Small B-cell Lymphoma
- Mantle Cell Lymphoma
- MALT Lymphoma
- Lymphoma
- Waldenstrm macroglobulinemia
- DLBCL
- Aggressive B-cell Lymphoma
- Diffuse B-cell Lymphoma
- Lymphatic Cancer
- Lymphosarcoma
- NHL
- Follicular Non-Hodgkin Lymphoma
- FL
- Nodular Lymphoma
- Lymphoplasmacytic Lymphoma', 'WM Lymphoma', 'Waldenstrom's Disease
- B-cell Non-Hodgkin Lymphoma
- B-NHL
- B-cell Lymphosarcoma
- Large B-cell Lymphoma
- Follicular Lymphatic Cancer
- Indolent Lymphoma
- Small Lymphocytic Lymphoma
- SLL
- Follicular Lymphoma Cancer
- MCL
- Mantle Cell Lymphoma Cancer
- Mucosa-associated lymphoid tissue lymphoma
- Extranodal marginal zone lymphoma
- B-cell lymphoma
ICD-10 Codes:
- C8330: Diffuse large B-cell lymphoma, unspecified site
- C8338: Diffuse large B-cell lymphoma, lymph nodes of multiple sites
- C8580: Other specified types of non-Hodgkin lymphoma, unspecified site
- C8290: Follicular lymphoma, unspecified, unspecified site
- C880: Waldenstrom macroglobulinemia
- C8510: Unspecified B-cell lymphoma, unspecified site
- C8331: Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
- C8200: Follicular lymphoma grade I, unspecified site
- C8300: Small cell B-cell lymphoma, unspecified site
- C8339: Diffuse large B-cell lymphoma, extranodal and solid organ sites
- C8298: Follicular lymphoma, unspecified, lymph nodes of multiple sites
- C8310: Mantle cell lymphoma, unspecified site
- C884: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
Also known as:
- Hodgkin Lymphoma
- Nodular Sclerosis Hodgkin Lymphoma
- Nodular Sclerosis Hodgkin Lymphoma (Multiple Lymph Nodes)
- Nodular Sclerosis Hodgkin Lymphoma in Head, Face, Neck Lymph Nodes
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Nodular Sclerosis Hodgkin Lymphoma in Chest Lymph Nodes
- Hodgkin's Disease', 'Hodgkin's Lymphoma
- NSHL', 'Nodular sclerosing Hodgkin's disease
- Hodgkin's Disease
- Lymphatic Cancer
- Reed-Sternberg Lymphoma
- NSHL widespread', 'Nodular sclerosing Hodgkin's disease in many lymph nodes
- NSHL in Head and Neck', 'Hodgkin's Lymphoma in Cervical Lymph Nodes
- NLPHL', 'Lymphocyte-predominant Hodgkin's Disease
- NSHL in Chest', 'Hodgkin's Lymphoma in Intrathoracic Lymph Nodes
ICD-10 Codes:
- C8190: Hodgkin lymphoma, unspecified, unspecified site
- C8110: Nodular sclerosis Hodgkin lymphoma, unspecified site
- C8170: Other Hodgkin lymphoma, unspecified site
- C8118: Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
- C8111: Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
- C8100: Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
- C8112: Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
Which procedures does Dr. Advani perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Ranjana Advani may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Advani's office.
Does Dr. Advani accept my insurance?
Dr. Advani accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Advani accept in Stanford, CA?
Dr. Advani in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Centene
Central California Alliance for Health
CVS Health (formerly Aetna)
Department of Defense / Tricare
Express Scripts
Medicaid
Medicare
UnitedHealthcare
View All Insurances
Where is Dr. Advani's office located?
Recognitions
Publications
Bevacizumab and cyclosphosphamide, doxorubicin
Leukemia & lymphoma, 2014
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte
Jourl of clinical oncology, 2014
Phase 2 study of VcR-CVAD with maintence rituximab for untreated mantle cell lymphoma
Blood, 2014
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
NEW ENGLAND JOURL OF MEDICINE, 2013
Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2013
Plasma Epstein-Barr virus D predicts outcome in advanced Hodgkin lymphoma
Blood, 2013
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastil B-Cell Lymphoma
NEW ENGLAND JOURL OF MEDICINE, 2013
Efficacy of abbreviated Stanford V chemotherapy
ANLS OF ONCOLOGY, 2013
The efficacy and tolerability of adriamycin, bleomycin
BRITISH JOURL OF HAEMATOLOGY, 2013
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally
JOURL OF CLINICAL ONCOLOGY, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
JOURL OF CLINICAL ONCOLOGY, 2013
Bruton Tyrosine Kise Inhibitor Ibrutinib
JOURL OF CLINICAL ONCOLOGY, 2013
Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin
JOURL OF CLINICAL ONCOLOGY, 2012
Brentuximab Vedotin in Transplant-ive Patients with Relapsed or Refractory Hodgkin Lymphoma
ONCOLOGIST, 2012
Brentuximab Vedotin
JOURL OF CLINICAL ONCOLOGY, 2012
Cardiac toxicity associated with bevacizumab
LEUKEMIA & LYMPHOMA, 2012
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011
MicroRs Are Independent Predictors of Outcome in Diffuse Large B
CLINICAL CANCER RESEARCH, 2011
Current concepts and controversies in the magement of early stage Hodgkin lymphoma
LEUKEMIA & LYMPHOMA, 2011
Comparison of conventiol prognostic indices in patients older than 60 years with diffuse large B
Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E., 2010
Risk stratification in extranodal tural killer/T-cell lymphoma
EXPERT REVIEW OF ANTICANCER THERAPY, 2010
Magement of T-cell and tural-killer-cell neoplasms in Asia
LANCET ONCOLOGY, 2009
Phase I Study of the Humanized Anti
JOURL OF CLINICAL ONCOLOGY, 2009
Impact of positive positron emission tomography
JOURL OF CLINICAL ONCOLOGY, 2007
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
JOURL OF CLINICAL ONCOLOGY, 2004
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
BRITISH JOURL OF HAEMATOLOGY, 2014
A multicenter phase II trial to determine the safety
LEUKEMIA & LYMPHOMA, 2013
Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2013
Non-Hodgkin's lymphomas, version 1.2013.
Jourl of the tiol Comprehensive Cancer Network, 2013
Gene Expression-Based Model Using Formalin-Fixed Paraffin
JOURL OF CLINICAL ONCOLOGY, 2013
Non-Hodgkin's Lymphomas, version 3.2012.
Jourl of the tiol Comprehensive Cancer Network, 2012
Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Single Cell Profiling of Circulating Tumor Cells
PLOS ONE, 2012
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
In situ vaccition against mycosis fungoides by intratumoral injection of a TLR9
BLOOD, 2012
Phase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies
INVESTIGATIOL NEW DRUGS, 2011
Hodgkin lymphoma.
Jourl of the tiol Comprehensive Cancer Network, 2011
NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
Lymphoma in Pregncy Initially Diagnosed as Vagil Intraepithelial Neoplasia and Lichen Planus
OBSTETRICS AND GYNECOLOGY, 2011
Non-Hodgkin's Lymphomas
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
JOURL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2011
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
SCIENCE TRANSLATIOL MEDICINE, 2011
In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
JOURL OF CLINICAL ONCOLOGY, 2010
Non-Hodgkin's Lymphomas
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2010
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Jourl of the tiol Comprehensive Cancer Network, 2010
Lymphoma cell VEGFR2 expression detected
BRITISH JOURL OF HAEMATOLOGY, 2010
The emerging role for rituximab in the treatment of nodular lymphocyte predomint Hodgkin lymphoma
CURRENT OPINION IN ONCOLOGY, 2009
Prognostic Factors in Primary Cutaneous Aplastic Large Cell Lymphoma
ARCHIVES OF DERMATOLOGY, 2009
Extranodal tural killer/T-cell lymphoma: current concepts in biology and treatment
LEUKEMIA & LYMPHOMA, 2009
Dymic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr
ONCOLOGY RESEARCH, 2009
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
JOURL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008
Evaluation and magement of angioimmunoblastic T-cell lymphoma
Clinical advances in hematology & oncology : H&O, 2008
Hodgkin disease/lymphoma.
Jourl of the tiol Comprehensive Cancer Network, 2008
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
Jourl of the tiol Comprehensive Cancer Network, 2008
Non-Hodgkin's lymphomas.
Jourl of the tiol Comprehensive Cancer Network, 2008
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
Jourl of the tiol Comprehensive Cancer Network, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
Jourl of the tiol Comprehensive Cancer Network, 2006
Magement of advanced stage Hodgkin lymphoma.
Jourl of the tiol Comprehensive Cancer Network, 2006
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)
ANLS OF ONCOLOGY, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003)
INVESTIGATIOL NEW DRUGS, 2005
A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003)
Investigatiol New Drugs,, 2005
Mitoxantrone, etoposide
JOURL OF CLINICAL ONCOLOGY, 2004
Phase I and pharmacokinetic study of BMS-188797, a new taxane alog
CLINICAL CANCER RESEARCH, 2003
Treatment of refractory
Blood, 1999
Bevacizumab and cyclosphosphamide, doxorubicin
Leukemia & lymphoma, 2014
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte
Journal of clinical oncology, 2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma
Blood, 2014
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades
Blood, 2013
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
NEW ENGLAND JOURNAL OF MEDICINE, 2013
Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma
Blood, 2013
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
NEW ENGLAND JOURNAL OF MEDICINE, 2013
Efficacy of abbreviated Stanford V chemotherapy
ANNALS OF ONCOLOGY, 2013
The efficacy and tolerability of adriamycin, bleomycin
BRITISH JOURNAL OF HAEMATOLOGY, 2013
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally
JOURNAL OF CLINICAL ONCOLOGY, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
JOURNAL OF CLINICAL ONCOLOGY, 2013
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
BLOOD, 2013
Bruton Tyrosine Kinase Inhibitor Ibrutinib
JOURNAL OF CLINICAL ONCOLOGY, 2013
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma
BLOOD, 2012
Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin
JOURNAL OF CLINICAL ONCOLOGY, 2012
Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma
ONCOLOGIST, 2012
Brentuximab Vedotin
JOURNAL OF CLINICAL ONCOLOGY, 2012
Cardiac toxicity associated with bevacizumab
LEUKEMIA & LYMPHOMA, 2012
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011
MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B
CLINICAL CANCER RESEARCH, 2011
Current concepts and controversies in the management of early stage Hodgkin lymphoma
LEUKEMIA & LYMPHOMA, 2011
Optimal therapy of advanced Hodgkin lymphoma.
Hematology / the Education Program of the American Society of Hematolo, 2011
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B
Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E., 2010
Risk stratification in extranodal natural killer/T-cell lymphoma
EXPERT REVIEW OF ANTICANCER THERAPY, 2010
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, , 2009
Management of T-cell and natural-killer-cell neoplasms in Asia
LANCET ONCOLOGY, 2009
Phase I Study of the Humanized Anti
JOURNAL OF CLINICAL ONCOLOGY, 2009
Impact of positive positron emission tomography on prediction of freedom from progression after
JOURNAL OF CLINICAL ONCOLOGY, 2007
Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine
LEUKEMIA & LYMPHOMA, 2007
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
JOURNAL OF CLINICAL ONCOLOGY, 2004
ACR appropriateness Criteria® pediatric Hodgkin lymphoma.
Pediatric blood & cancer, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
BRITISH JOURNAL OF HAEMATOLOGY, 2014
ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma
ONCOLOGY-NEW YORK, 2013
A multicenter phase II trial to determine the safety
LEUKEMIA & LYMPHOMA, 2013
Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013
Non-Hodgkin's lymphomas, version 1.2013.
Journal of the National Comprehensive Cancer Network, 2013
Gene Expression-Based Model Using Formalin
JOURNAL OF CLINICAL ONCOLOGY, 2013
Non-Hodgkin's Lymphomas, version 3.2012.
Journal of the National Comprehensive Cancer Network, 2012
Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Single Cell Profiling of Circulating Tumor Cells
PLOS ONE, 2012
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Interim-treatment quantitative PET parameters predict progression
RADIATION ONCOLOGY, 2012
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9
BLOOD, 2012
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed
CLINICAL CANCER RESEARCH, 2012
Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine
INVESTIGATIONAL NEW DRUGS, 2011
Hodgkin lymphoma.
Journal of the National Comprehensive Cancer Network, 2011
NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
Prediction of survival in diffuse large B
BLOOD, 2011
Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus
OBSTETRICS AND GYNECOLOGY, 2011
Non-Hodgkin's Lymphomas
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2011
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
SCIENCE TRANSLATIONAL MEDICINE, 2011
Prediction of Survival In Diffuse Large B
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, , 2010
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
JOURNAL OF CLINICAL ONCOLOGY, 2010
ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma
CURRENT PROBLEMS IN CANCER, 2010
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed
CLINICAL CANCER RESEARCH, 2010
Non-Hodgkin's Lymphomas
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network, 2010
Interim positron emission tomography scans in diffuse large B-cell lymphoma
BLOOD, 2010
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival
BRITISH JOURNAL OF HAEMATOLOGY, 2010
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma
CURRENT OPINION IN ONCOLOGY, 2009
Prognostic Factors in Primary Cutaneous Anapl
ARCHIVES OF DERMATOLOGY, 2009
Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR)
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J.,
Targeting CD40 in Waldenstrom's Macroglobulinemia
CLINICAL LYMPHOMA & MYELOMA, 2009
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment
LEUKEMIA & LYMPHOMA, 2009
Dynamic CD8 T-Cell Responses to Tumor
ONCOLOGY RESEARCH, 2009
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008
Evaluation and management of angioimmunoblastic T-cell lymphoma
Clinical advances in hematology & oncology : H&O, 2008
Hodgkin disease/lymphoma.
Journal of the National Comprehensive Cancer Network, 2008
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with
BLOOD, 2008
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
Journal of the National Comprehensive Cancer Network, 2008
Non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network, 2008
Non-Hodgkin lymphoma of the breast
CANCER, 2007
Treatment of mantle cell lymphoma: Current approach and future directions
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006
Staging accuracy in mycosis fungoides
ARCHIVES OF DERMATOLOGY, 2006
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network, 2006
Management of advanced stage Hodgkin lymphoma.
Journal of the National Comprehensive Cancer Network, 2006
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)
ANNALS OF ONCOLOGY, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003)
INVESTIGATIONAL NEW DRUGS, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003)
Investigational New Drugs,, 2005
Mitoxantrone, etoposide
JOURNAL OF CLINICAL ONCOLOGY, 2004
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog
CLINICAL CANCER RESEARCH, 2003
A phase I trial of doxorubicin, paclitaxel
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litc, 2001
Treatment of refractory
Blood, 1999
What is Dr. Advani's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Advani's National Provider Identifier (NPI) number is 1639225121.
What common questions do patients ask about Dr. Advani?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Advani
What is Dr. Ranjana Advani's specialty?
Dr. Advani is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Advani to book an appointment today.
Is this Dr. Ranjana Advani affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Advani is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Ranjana Advani accepting new patients in Stanford, CA?
Yes, Dr. Ranjana Advani is accepting new patients at this time.
Does Dr. Ranjana Advani offer online booking?
Please contact Dr. Advani's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Ranjana Advani?
Please contact Dr. Advani's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Ranjana Advani have?
Dr. Ranjana Advani is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients